{"product_id":"global-predictive-diagnostics-market-2023-2030","title":"Global Predictive Diagnostics Market - 2023-2030","description":"\u003cp\u003eGlobal Predictive Diagnostics Market - 2023-2030\u003c\/p\u003e\n\n\u003cp\u003eMarket Overview\u003c\/p\u003e\n\n\u003cp\u003eThe Global \"\"Predictive Diagnostics Market\"\"  size was valued at US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period (2023-2030).\u003c\/p\u003e\n\n\u003cp\u003ePredictive diagnostics employs customized data and a suite of diagnostic devices to deliver precise, real-time insights and identify potential problems. By integrating molecular innovations, genomics applications, and rapid R\u0026amp;D processes, Predictive diagnostics can assist deliver impactful and measurable advancements to operations.\u003c\/p\u003e\n\n\u003cp\u003eMarket Dynamics\u003c\/p\u003e\n\n\u003cp\u003eThe global predictive diagnostics market is driven by technological advancements, growing adoption of predictive diagnostics in research and development, rising lifestyle disease, and an increasingly health-conscious population.\u003c\/p\u003e\n\n\u003cp\u003eIncreasing benefits of predictive diagnostics in healthcare drives market growth\u003c\/p\u003e  \n\n\u003cp\u003eThe technological advancements in diagnostics sectors drive the market in the forecast period. According to the Philips report, June 2020, predictive analytics in healthcare help detect early signs of patient degeneration in intensive care units and general wards, recognize at-risk patients in their residences to prevent hospital readmissions, and prevent avoidable downtime of medical equipment. Predictive diagnostics allows combining data from multiple sources – including hospital-based electronic medical records, fall detection pendants, and the historical use of medical alert services – to identify seniors at risk of emergency transport in the next 30 days. Predictive diagnostics allows healthcare providers to reach out to a senior person before a fall or another medical complication occurs, preventing unnecessary hospital readmissions and reducing transportation, acute care, and rehabilitation costs.\u003c\/p\u003e\n\n\u003cp\u003eIn addition, the market players are applying the market strategies such as product launches and collaboration to expand their business. For instance, in October 2021, bioMérieux - a French multinational biotechnology firm focusing on in-vitro diagnostics - launched predictive Diagnostics, the company’s new offering in food safety and food quality. Also, in September 2022, QIAGEN and Neuron23 Inc., a biotechnology organization focused on designing precision medicines for genetically defined neurological and immunological diseases, agreed to create a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson’s disease. In this agreement, QIAGEN will design and validate a clinical trial assay that will detect a mixture of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson’s disease to an LRRK2 inhibitor. Furthermore, this partnership will support the clinical development of Neuron23’s drug candidate, which is presently in the late stages of preclinical development. Subject to further clinical development, the agreement also enfolds options for developing additional companion diagnostics.\u003c\/p\u003e\n\n\u003cp\u003eThe lack of expertise in predictive diagnostics testing will hamper the growth of the market\u003c\/p\u003e\n\n\u003cp\u003eHowever, less reliability of biomarkers for identifying chronic degenerative diseases and lack of expertise in predictive diagnostics testing will restrain the market in the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eCOVID-19 Impact Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe appearance of COVID-19 positively impacted the global predictive diagnostics market.  As per the article published in Advances in Biomarker Sciences and Technology in 2020, biomarkers are particularly important during a pandemic state since they can enhance the development and approval of new, innovative drugs and biological products, particularly in the field of vaccines. Biomarkers can be applied to describe observable characteristics of certain diseases and determine optimal treatments based on these phenotypes and genotypes; thence, they have received substantial attention. In particular, respiratory disease biomarkers, such as those associated with acute respiratory distress syndrome (ARDS), have been associated with increased mortality (IL-8, ICAM-1) and improved survival (nitric oxide). These biomarkers play a pivotal role in predicting future complications or disease severity and could be useful as an indicator for COVID-19 prognosis.\u003c\/p\u003e\n\n\u003cp\u003eSegment Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe oncology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)\u003c\/p\u003e      \n\n\u003cp\u003eThe oncology segment accounts for the largest market share. Cancer is the foremost cause of death worldwide. The most familiar cancers are breast, colon, lung, rectum, and prostate. Cancer accounted for almost 10 million deaths in 2020 or nearly one in six.\u003c\/p\u003e\n\n\u003cp\u003eAs per the article published in Frontiers in Oncology in September 2022, predictive biomarkers in the context of progressive disease treated with chemotherapy are also included. A meta-analysis of clinicopathological features that predict necrosis\/fibrosis in retroperitoneal residual masses of non-seminoma patients, including histopathological features in the orchiectomy specimen (absence of teratoma, presence of seminoma), as well as serum tumor markers (normal HCG and AFP, elevated LDH) and size of the mass (\u0026gt;50% change in size, smaller residual mass size). A\u003c\/p\u003e\n\n\u003cp\u003eAlso, identified features that predict the development of choriocarcinoma syndrome (a severe complication, challenging to treat and with considerable mortality) in poor-risk germ cell tumor patients, including metastatic lung involvement of more than half and ECOG PS around two. Rising cancer cases and demand for predictive diagnostics drives the market worldwide.\u003c\/p\u003e\n\n\u003cp\u003eGeographical Analysis\u003c\/p\u003e\n\n\u003cp\u003eNorth America region holds the largest market share of the global predictive diagnostics market\u003c\/p\u003e\n\n\u003cp\u003eNorth America dominates the market for predictive diagnostics and is anticipated to show an equivalent trend over the forecast period. The market is driven by improved healthcare infrastructure, the increasing incidence of infectious disease, active regional key players, and easy availability of products in the region.\u003c\/p\u003e\n\n\u003cp\u003eThe market players are offering predictive diagnostics in the North American region. For instance, F. Hoffmann-La Roche Ltd provides predictive diagnostics solutions for oncology, cardiovascular disease, infectious disease, respiratory disease, autoimmune disease and more.\u003c\/p\u003e\n\n\u003cp\u003eIn addition, key players are adopting the market strategies such as acquisition and product launches. For instance, in December 2021, Roche acquired the TIB Molbiol Group. TIB Molbiol will continue to work as a subsidiary within the Diagnostics division. Roche and TIB Molbiol will create their capabilities for the fast development of assays for emerging pathogens and potential health threats, such as infectious diseases.\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eThe predictive diagnostics market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Abbott Molecular, Almac Group Ltd., Ambry Genetics Corporation, BioGenex, Epistem Ltd., F. Hoffmann-La Roche Ltd., Genomic Health, Inc., MDxHEALTH, Inc., Myriad Genetics, Inc., OPKO Health, Inc, Prometheus Laboratories Inc., Proteomics International Laboratories Ltd, and QIAGEN N.V., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the predictive diagnostics market globally.\u003c\/p\u003e\n\n\u003cp\u003eFor instance,\u003cbr\u003e\n• In September 2021, Janssen-a pharmaceutical subsidiary of Johnson \u0026amp; Johnson - introduced its nine-month startup accelerator - a program for the digital health startup space to gain innovative ideas on predictive diagnostics to discover precision treatments and therapies.\u003c\/p\u003e\n\n\u003cp\u003eQIAGEN\u003c\/p\u003e\n\n\u003cp\u003eOverview:\u003c\/p\u003e\n\n\u003cp\u003eQIAGEN is a German organization founded in 1984 and headquartered in Hilden, Germany. It delivers the solutions for molecular testing and provides the answer from the building blocks of life- DNA, RNA, and protein to the customers to unblock the new insights.\u003c\/p\u003e\n\n\u003cp\u003eProduct Portfolio:\u003c\/p\u003e\n\n\u003cp\u003eNextSeq 550Dx:  This instrument is FDA-regulated and CE-in vitro diagnostic (IVD) marked, allowing clinical laboratories to design and execute a broad range of applications, from Next Generations sequencing solutions IVD assays using targeted panels to clinical research applications that include techniques from targeted panels to whole genomes.\u003c\/p\u003e\n\n\u003cp\u003eThe global predictive diagnostics market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 200 Pages \/ MCW16225650","offer_id":47640079860018,"sku":null,"price":5220.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-predictive-diagnostics-market-2023-2030","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}